A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
| Status: | Withdrawn |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/16/2019 |
| Start Date: | November 2010 |
| End Date: | January 10, 2018 |
A Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® for the Prevention of Cardiac Allograft Vasculopathy in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients.
The purpose of this study is to test the hypothesis that administering Thymoglobulin®
induction therapy early after transplant prevents the development of cardiac allograft
vasculopathy (CAV). CAV accounts for a significant number of deaths in cardiac recipients
after the first year of transplant. At 5 years post-transplant 30% of the deaths are due to
CAV. With the exception of re-transplantation the available treatments for CAV are only
effective at inhibiting its progression.
CAV involves only the allograft and spares the native arteries, suggesting an immunologic
basis for the disease. However, both immunological and non-immunological factors contribute
to the development of CAV. The established immunological risk factors are recurrent rejection
and humoral/antibody-mediated rejection (AMR). Non-immunological risk factors identified
include preservation injury, the cause of donor death, donor graft ischemic time, and
cytomegalovirus infection1. It is hypothesized that these factors increase the risk of
developing CAV by causing early endothelial damage to the graft, which then could promote
increased lymphocyte-endothelial interactions and the production of anti-endothelial
antibodies2. The investigators hypothesized that Thymoglobulin induction therapy would
prevent the development of CAV because its polyclonal nature allows Thymoglobulin to target
all the potential mechanisms that contribute to the development of CAV—T-cell activation,
B-cell activation, antibody formation, induction of tolerance, and modulation of
lymphocyte-endothelium interactions3. Because the mechanism by which Thymoglobulin affects
the immune system are still poorly understood, the investigators will also study how
Thymoglobulin changes the immune system over time in the heart transplant recipient as a
secondary objective.
induction therapy early after transplant prevents the development of cardiac allograft
vasculopathy (CAV). CAV accounts for a significant number of deaths in cardiac recipients
after the first year of transplant. At 5 years post-transplant 30% of the deaths are due to
CAV. With the exception of re-transplantation the available treatments for CAV are only
effective at inhibiting its progression.
CAV involves only the allograft and spares the native arteries, suggesting an immunologic
basis for the disease. However, both immunological and non-immunological factors contribute
to the development of CAV. The established immunological risk factors are recurrent rejection
and humoral/antibody-mediated rejection (AMR). Non-immunological risk factors identified
include preservation injury, the cause of donor death, donor graft ischemic time, and
cytomegalovirus infection1. It is hypothesized that these factors increase the risk of
developing CAV by causing early endothelial damage to the graft, which then could promote
increased lymphocyte-endothelial interactions and the production of anti-endothelial
antibodies2. The investigators hypothesized that Thymoglobulin induction therapy would
prevent the development of CAV because its polyclonal nature allows Thymoglobulin to target
all the potential mechanisms that contribute to the development of CAV—T-cell activation,
B-cell activation, antibody formation, induction of tolerance, and modulation of
lymphocyte-endothelium interactions3. Because the mechanism by which Thymoglobulin affects
the immune system are still poorly understood, the investigators will also study how
Thymoglobulin changes the immune system over time in the heart transplant recipient as a
secondary objective.
Inclusion Criteria:
- Subjects must be undergoing their first allograft transplant
- Men and non-pregnant women must be 18 to 70 years old
- Women of childbearing potential must have a negative serum pregnancy test within 7
days prior to transplantation. The sensitivity must be equal to at least 50 mIU/mL.
(Urine test is allowed in addition to serum test in patients where serum results are
delayed).
- Women of childbearing potential must use two reliable forms of contraception
simultaneously. Effective contraception must be used before beginning study drug
therapy, and for 4 months following discontinuation of study drug therapy.
- Subjects must be willing and be capable of understanding the purpose and risks of the
study and must sign a statement of informed consent.
Exclusion Criteria:
- Previous organ transplants
- Patients receiving multiple organs
- Patients > 250 lbs or 114 kgs
- Patients requiring VAD upon completion of transplantation surgery. [Patients who
require LVADs prior to surgery may be enrolled as long as no presurgery
immunosuppressives (see list in Appendix B) were administered.]
- Women lactating, pregnant, or of childbearing potential, not using, or who are
unwilling to use two reliable forms of contraception simultaneously during the study.
- Men who are not using a reliable contraceptive method
- History of a psychological illness or condition which would interfere with the
patient's ability to understand the requirements of the study
- White blood cell count ≤ 2500/mm3, or platelets ≤ 50,000/mm3, or hemoglobin ≤ 6g/dL
- HIV-1, HTLV-1, chronic Hepatitis B, or chronic Hepatitis C infection
- Documented or strong suspicion for pre-operative active infection that has not yet
been adequately treated with the recommended course of antimicrobial therapy
- Presence of any chronic myelosuppressive disease or agent that has resulted in either
chronic leucopenia or chronic thrombocytopenia
- Active peptic ulcer disease
- Patients who have received within the past 30 days or require concomitant treatment
with other investigational drugs (except for those listed in section 8.6 "Concomitant
treatment") or immunosuppressive medications that are prohibited for this study
(Appendix B)
We found this trial at
1
site
Click here to add this to my saved trials
